MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose’s Electronic Dry Powder Inhaler
The aim of the investigation is to demonstrate the ability to wirelessly upload dosing and compliance information from the inhaler to a web-based server for data management and reporting. The SmartinhalerLive technology, providing global roaming wireless, is a natural extension of MicroDose’s electronic inhaler features and will facilitate better communication between the physician, patient and pharmaceutical company to improve all aspects of care.
The combined system would have benefits in both the clinical trials setting and with in-market products. By improving compliance through reminder features, and through real-time tracking of compliance, patient safety and clinical trial data management are improved. Improved control and monitoring of compliance can significantly reduce the number of patients enrolled per Phase II or Phase III clinical studies. In marketed products, the system represents a move to more personalized care, giving a better understanding of drug usage and patient response to therapy, and improved compliance and adherence.
About the MicroDose DPI
The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance versus other inhalers, for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture. Microdose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.
About MicroDose Technologies
MicroDose Technologies, Inc., based in
MicroDose’s partnered programs include; multi-product development and licensing agreements with Merck and Co. and Novartis, the development of an inhaled insulin product through MicroDose’s QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense, in collaboration with the
About Nexus6 and SmartinhalerLive(TM)
Nexus6 Limited is a privately held
Nexus6 SmartinhalerLive(TM) devices monitor and report patients’ medication usage to their healthcare partners, and are used in pharmaceutical clinical trials and respiratory disease management applications for chronic obstructive pulmonary disease, asthma and cystic fibrosis.
SmartinhalerLive(TM) uses wireless communications technology to provide real time data collection and reporting from drug delivery devices.
SOURCE MicroDose Technologies, Inc.